Daewoong Pharma (069620) — Capital Reinvestment Ratio

Latest as of September 2025: 1.26x

Daewoong Pharma (069620) has a Capital Reinvestment Ratio of 1.26x as of September 2025, meaning it reinvests 1% of its operating cash flow (₩57.53 Billion) in capital expenditures (₩72.21 Billion). See Daewoong Pharma (069620) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

1.26x
Capex / Operating Cash Flow

Operating Cash Flow

₩57.53 Billion
KRW

Capital Expenditures

₩72.21 Billion
KRW

Data as of

Sep 2025
Most recent filing

Daewoong Pharma Capital Reinvestment Ratio (2007–2024)

This chart tracks Daewoong Pharma's Capital Reinvestment Ratio across 16 annual periods.

Annual Capital Reinvestment Ratio for Daewoong Pharma (2007–2024)

Year-by-year Capital Reinvestment Ratio for Daewoong Pharma from 2007 to 2024. For live market cap and broader valuation context, see Daewoong Pharma (069620) market capitalisation.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2024 4.45x ₩51.49 Billion ₩229.00 Billion ▲ +396.8%
2023 0.90x ₩132.57 Billion ₩118.67 Billion ▲ +62.2%
2022 0.55x ₩118.21 Billion ₩65.23 Billion ▼ -24.1%
2021 0.73x ₩39.99 Billion ₩29.09 Billion ▲ +177.3%
2020 0.26x ₩100.98 Billion ₩26.49 Billion ▼ -32.3%
2019 0.39x ₩57.60 Billion ₩22.31 Billion ▼ -67.7%
2018 1.20x ₩47.50 Billion ₩56.99 Billion ▲ +80.4%
2017 0.67x ₩103.94 Billion ₩69.12 Billion ▼ -93.7%
2016 10.62x ₩15.38 Billion ₩163.25 Billion ▲ +300.5%
2015 2.65x ₩35.89 Billion ₩95.13 Billion ▲ +49.5%
2014 1.77x ₩25.95 Billion ₩46.00 Billion ▲ +404.3%
2013 0.35x ₩54.16 Billion ₩19.04 Billion ▼ -33.4%
2012 0.53x ₩45.02 Billion ₩23.77 Billion ▲ +1.7%
2011 0.52x ₩78.82 Billion ₩40.92 Billion ▼ -54.0%
2008 1.13x ₩31.33 Billion ₩35.35 Billion ▼ -18.8%
2007 1.39x ₩25.81 Billion ₩35.89 Billion —
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow